Product Wiki · Recalls · EU Safety Gate (RAPEX)

Lavi Salipure Peeling — recall A12/03121/24

EU Safety Gate (RAPEX) · Spain · 2024-11-15 · Serious risk

Machine-translated with AI — the facts come from the issuing authority’s own notice (linked on this page); this language version was translated automatically by an AI model and is not reviewed. The original-language notice is authoritative. How we use AI →
Agency
EU Safety Gate (RAPEX)
Recall identifier
A12/03121/24
Date of alert
2024-11-15
Country / jurisdiction
Spain
Risk level
Serious risk
Risk type
Chemical
Brand
Laviderm
Product category
Cosmetics
Product type
Skin peeling product
Barcode (EAN/GTIN)
8429007063085
Reported risk: El producto tiene una concentración excesiva de ácido salicílico (valor medido: 27%). El ácido salicílico causa daños oculares graves y puede provocar quemaduras químicas cuando se aplica sobre la piel. El producto no cumple con el Reglamento de Productos Cosméticos.
Action taken by the authority
Type of economic operator taking notified measure
Manufacturer
Category of measure
Recall of the product from end users
Machine translation. This page was translated automatically from the English record we hold of the issuing authority’s notice. The English original is shown below and the authority’s own notice is linked above — both take precedence over this translation.

Product Name (original English): Lavi Salipure Peeling

Risk Description (original English): The product has an excessive concentration of salicylic acid (measured value: 27%). Salicylic acid causes serious eye damage and may cause chemical burns when applied on the skin.

Primary source: https://ec.europa.eu/safety-gate-alerts/screen/webReport/alertDetail/10091942

Verify each fact at the issuing agency before acting. Recall scope, affected lots, and remediation instructions may be updated by the agency after our last sync.

ProductGuru indexes recall and safety-alert records from ~30 public agency registries. We are not lawyers, regulators or product-safety consultants. This page restates what the named agency published; consult the primary source above (or qualified counsel in your jurisdiction) before any commercial, medical or safety decision.